CClinicalTrials.gg
Sign In
CompletedNCT03140748PERIGLUC1Updated Sep 19, 2025

Kinetics of Serum β-D-glucan During Peritonitis With Candida in Resuscitation

An interventional study of To evaluate the initial levels and kinetics of serum β-D-glucan in Peritonitis Infectious and Candida Infection, sponsored by Centre Hospitalier Universitaire, Amiens. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-19.

Sponsored by Centre Hospitalier Universitaire, Amiens · Not applicable, Interventional, and Screening

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Intraabdominal fungal infections with Candida are constantly increasing. Their diagnosis and treatment is difficult. Morbidity and mortality are high. Β-D-Glucan has been proposed as a marker of systemic fungal infection in candidemia. Moreover, its kinetics is associated with therapeutic success. On the other hand, there are no data on intraabdominal infections that are much more frequent. The objective of the study is to evaluate the initial levels of β-D-glucan and its daily kinetics during the treatment of fungal peritonitis in resuscitation compared to a control group with a yeast-free peritonitis.

02

Conditions studied

  • Peritonitis Infectious
  • Candida Infection

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Major Patient (age ≥ 18 years)
  • Community or associated peritonitis, operated and hospitalized in resuscitation
  • Affiliation to a social security scheme

Exclusion criteria

Exclusion Criteria:

  • Allergy known to echinocandins
  • Dying Patient
  • Limitation of care
  • Predictable duration of follow-up ≤ 10 days
  • Transfusion within 3 months
  • Patient minor, patient under guardianship or curatorship
04

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Other
    Patients with fungal peritonitis

    Other: To evaluate the initial levels and kinetics of serum β-D-glucan

  • Other
    Patients with peritonitis without yeast

    Other: To evaluate the initial levels and kinetics of serum β-D-glucan

Interventions

  • OtherTo evaluate the initial levels and kinetics of serum β-D-glucan

    To evaluate the initial levels and kinetics of serum β-D-glucan during fungal peritonitis compared to a control group of yeast-free peritonitis

05

What researchers measure

Primary outcomes

  1. Blood determination of serum β-D-glucan kinetics in patients with peritonitis

    Blood determination of serum β-D-glucan kinetics in patients with peritonitis

    Time frame: 28 days

06

Study locations

1 site
  • CHU Amiens Picardie
    Amiens, Picardie 80054, France
07

References and documents

Publications

  • Dupont H, Malaquin S, Villeret L, Macq PY, Ammenouche N, Tinturier F, Diouf M, Rumbach M, Chouaki T. Is ss-d-glucan Relevant for the Diagnosis and Follow-Up of Intensive Care Patients with Yeast-Complicated Intra-Abdominal Infection? J Fungi (Basel). 2022 May 6;8(5):487. doi: 10.3390/jof8050487. PubMed 35628743 ↗
08

Registry details

Key details

Study ID
NCT03140748
Lead sponsor
Centre Hospitalier Universitaire, Amiens
Responsible party
Sponsor
First posted
May 4, 2017
Start date
May 1, 2018
Primary completion
Aug 22, 2021
Completion
Jun 1, 2023
Last update
Sep 19, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Candidiasis→

Other studies from this sponsor

Centre Hospitalier Universitaire, Amiens

Start the discussion